Positive developments mount in health and biotech, including InBody and Mezoo

InBody 5month 28day announced that it would provide an AI-based body composition management service through an integration with Naver Healthcare. The company said the integration would make it possible to connect and manage individuals’ body composition data through a healthcare platform. It said demand for body composition analysis was expected to rise as the obesity management market expands, separately from announcements by health authorities.

Mezoo 5month 28day disclosed that it had obtained manufacturing approval for a next-generation product. The company said the approval made commercial production of the product possible. Mezoo’s share price rose sharply immediately after the announcement.

D&D Pharmatech 5month 27day hit the daily upper price limit. The company announced a related disclosure and an increase in trading activity. Trading value that day was reported to have exceeded its usual level.

Daewoong, Seers, and TR announced that they would jointly develop a next-generation smart ward solution. The three companies said they were pursuing a project to integrate the systems and services required for hospital operations. Further disclosures from each company are expected to provide the scope of the business and specific schedules.

Deepnoid said it had published a research paper on AI related to colon pathology5month 28day. The company disclosed that it would continue developing pathology AI solutions based on the research findings. Along with announcing the publication, the company said it was assessing the solutions’ potential for clinical application.

In summary, as announcements of integration, regulatory approvals, and research results continued in the health and biotech sectors, related companies saw share-price volatility alongside their disclosures. Each company is expected to make further announcements concerning additional disclosures, product commercialization, and clinical schedules.